Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2017-08-04

FDA Approved: LESCOL XL — Supplemental Application (Sandoz Inc)

View source ↗

Summary

FDA is reviewing a supplemental application for LESCOL XL (fluvastatin sodium) from Sandoz Inc., likely involving changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LESCOL XL (Fluvastatin sodium)

Snippet

SUPPL AP for LESCOL XL (FLUVASTATIN SODIUM)